Telix Pharmaceuticals has agreed to acquire Isotope Technologies Munich (ITM) in a deal worth up to $1.65B upfront, potentially reaching about $2.35B with milestones, creating a more vertically integrated radiopharmaceutical platform. ITM’s lead asset, ITM-11 (177Lu-edotreotide), is in late-stage development and recently received a complete response letter from the FDA tied to chemistry, manufacturing and controls and third-party facility items. The merger is positioned to expand Telix’s manufacturing footprint and isotope supply capabilities while consolidating development pipelines in a market increasingly challenged by supply constraints and manufacturing complexity. Analysts framed the move as Telix pushing further into territory occupied by larger incumbents, betting that scale can translate into execution advantages. The transaction also lands amid continued regulatory and commercial scrutiny across radiopharma assets, where CMC and facility readiness often determine timelines as much as clinical performance. By pairing ITM’s pipeline with Telix’s infrastructure, both companies aim to improve global throughput for radionuclide production and radioligand drug development.